The Biden administration proposes once again to push back, this time from March 22 to July 20, the effective date of the Trump administration’s controversial final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price centers pay for those drugs under the 340B program.
The rule originally was set to take effect Jan. 22. The new administration on Jan. 21 froze it for 60 days “for further review and consideration of new regulations.” In a Federal Register notice today, it announced a five-day comment period on its proposal for a second 60-day delay, with comments due on or before March 14.
The Biden administration proposes once again to push back, this time from March 22 to July 20, the effective date of the Trump administration’s controversial final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price centers pay for those drugs under the 340B program.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
